Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2021 Financial Results
25 January 2022 - 12:38AM
Business Wire
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi
therapeutics company, announced today that it will report financial
results for the fourth quarter and year ending December 31, 2021 on
Thursday, February 10, 2022, before the U.S. financial markets
open.
Management will provide an update on the Company and discuss
fourth quarter and year-end 2021 results as well as expectations
for the future via conference call on Thursday, February 10, 2022
at 8:30 am ET. To access the call, please dial 877-312-7507
(domestic) or +1-631-813-4828 (international) five minutes prior to
the start time and refer to conference ID 9729709. A replay of the
call will be available beginning at 11:30 am ET on the day of the
call. To access the replay, please dial 855-859-2056 (domestic) or
+1-404-537-3406 (international) and refer to conference ID
9729709.
A live audio webcast of the call will be available on the
Investors section of the Company’s website at
www.alnylam.com/events. An archived webcast will be available on
the Alnylam website approximately two hours after the event.
About Alnylam Pharmaceuticals
Alnylam (Nasdaq: ALNY) has led the translation of RNA
interference (RNAi) into a whole new class of innovative medicines
with the potential to transform the lives of people afflicted with
rare and prevalent diseases with unmet need. Based on Nobel
Prize-winning science, RNAi therapeutics represent a powerful,
clinically validated approach yielding transformative medicines.
Since its founding 20 years ago, Alnylam has led the RNAi
Revolution and continues to deliver on a bold vision to turn
scientific possibility into reality. Alnylam’s commercial RNAi
therapeutic products are ONPATTRO® (patisiran), GIVLAARI®
(givosiran), OXLUMO® (lumasiran) and Leqvio® (inclisiran) being
developed and commercialized by Alnylam’s partner, Novartis.
Alnylam has a deep pipeline of investigational medicines, including
six product candidates that are in late-stage development. Alnylam
is executing on its “Alnylam P5x25” strategy to deliver
transformative medicines in both rare and common diseases
benefiting patients around the world through sustainable innovation
and exceptional financial performance, resulting in a leading
biotech profile. Alnylam is headquartered in Cambridge, MA. For
more information about our people, science and pipeline, please
visit www.alnylam.com and engage with us on Twitter at @Alnylam, on
LinkedIn, or on Instagram.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220124005478/en/
Alnylam Pharmaceuticals, Inc. Christine Regan Lindenboom
(Investors and Media)
617-682-4340
Josh Brodsky
(Investors) 617-551-8276
Alnylam Pharmaceuticals (NASDAQ:ALNY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alnylam Pharmaceuticals (NASDAQ:ALNY)
Historical Stock Chart
From Apr 2023 to Apr 2024